Intellia Therapeutics has said it will reduce its headcount by 27% this year and shelve early-stage R&D programmes as it puts its resources behind two priority drug candidates. The specialist in ...

Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine ...

Intellia Therapeutics doses first patient in MAGNITUDE-2 phase 3 study of nexiguran ziclumeran: Cambridge, Massachusetts Saturday, April 5, 2025, 18:00 Hrs [IST] Intellia Therapeu ...

Intellia Therapeutics, Inc. NTLA is developing its lead CRISPR-based, in vivo genome-editing candidate, nexiguran ziclumeran (nex-z, formerly known as NTLA-2001) for the treatment of transthyretin ...

CM. Read why NTLA stock has potential with upcoming 2025 data and a growing $12B market for Transthyretin Amyloidosis.

CAMBRIDGE, Mass., March 26, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based ...